461 related articles for article (PubMed ID: 23040351)
21. [Bisphosphonate and osteonecrosis of the jaw.].
Taguchi A
Clin Calcium; 2017; 27(2):225-231. PubMed ID: 28123124
[TBL] [Abstract][Full Text] [Related]
22. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
24. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
Van Poznak C
Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
[TBL] [Abstract][Full Text] [Related]
25. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.
Spanou A; Lyritis GP; Chronopoulos E; Tournis S
Oral Dis; 2015 Nov; 21(8):927-36. PubMed ID: 25732104
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
28. [Bisphosphonate-related osteonecrosis of the jaw].
Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
[TBL] [Abstract][Full Text] [Related]
29. [Bisphosphonates for myeloma patients].
Miwa A
Nihon Rinsho; 2007 Dec; 65(12):2315-37. PubMed ID: 18069279
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
Khan AA; Morrison A; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Al Dabagh R; Davison KS; Kendler DL; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Bone Miner Res; 2015 Jan; 30(1):3-23. PubMed ID: 25414052
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
Grant BT; Amenedo C; Freeman K; Kraut RA
J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
[TBL] [Abstract][Full Text] [Related]
32. [The risk of bisphosphonate-related osteonecrosis of the jaw].
Polymenidi I; Trombetti A; Carballo S
Rev Med Suisse; 2014 Oct; 10(446):1930-4. PubMed ID: 25438377
[TBL] [Abstract][Full Text] [Related]
33. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy.
Fleisher KE; Jolly A; Venkata UD; Norman RG; Saxena D; Glickman RS
J Oral Maxillofac Surg; 2013 Mar; 71(3):513-9. PubMed ID: 22999296
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
37. Drug-induced osteonecrosis of the jaw: the state of the art.
Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
[TBL] [Abstract][Full Text] [Related]
38. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.
Jeffcoat M; Watts NB
Gen Dent; 2008; 56(1):96-102; quiz 103-4, 111-2. PubMed ID: 18254568
[TBL] [Abstract][Full Text] [Related]
39. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
40. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]